Dr Judy Garber speaks to ecancer about the longer term follow up (6.1 years) results from the OlympiA trial. This trial looks at adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer.

She explains that previous reporting showed an improvement with olaparab in invasive disease and overall survival advantage,

Dr Garber reports that all of these improvements have been maintained and across all sub groups.